● DIRECTORY · ALL PROFILES156 PROFILES · INDEXED
The directory.
A reference of 156 peptide profiles — mechanisms, dosing, research, and legal status, compiled from published studies and reader reports.
SHOWING · 6 RESULTS · "Semaglutide"
6 profiles
001
Semaglutide
Ozempic · Wegovy · Rybelsus
Weight Loss
Semaglutide is a GLP-1 receptor agonist originally developed for type 2 diabetes (Ozempic) and later approved for weight management (Wegovy).
Prescription
→
002
Tirzepatide
Mounjaro · Zepbound
Weight Loss
Tirzepatide is a dual GIP/GLP-1 receptor agonist developed by Eli Lilly.
Prescription
→
003
Liraglutide
Victoza · Saxenda
Weight Loss
Liraglutide is a GLP-1 receptor agonist developed by Novo Nordisk, FDA-approved as Victoza for type 2 diabetes (2010) and Saxenda for weight management (2014).
Prescription
→
004
Cagrilintide
AM833 · CagriSema component · NN9838
Weight Loss
Cagrilintide is a long-acting synthetic amylin analog developed by Novo Nordisk, designed for once-weekly subcutaneous dosing.
Research Only
→
005
Orforglipron
LY3502970
Weight Loss
Orforglipron (LY3502970) is an oral, once-daily, non-peptide small-molecule GLP-1 receptor agonist developed by Eli Lilly (originally discovered by Chugai Pharmaceutical).
Research Only
→
006
CagriSema
Cagrilintide-Semaglutide · CagriSema 2.4/2.4 · amylin-GLP-1 combination
Weight Loss
CagriSema is a fixed-dose co-formulation combining cagrilintide (a long-acting amylin analogue) and semaglutide (a GLP-1 receptor agonist), both at 2.
Research Only
→